Inflammatory Bowell
Review | Pediatric-onset inflammatory bowel disease: recent developments
27 Jul, 2023 | 12:57h | UTCInflammatory bowel disease: recent developments – Archives of Disease in Childhood
Systematic Review | Vedolizumab for induction and maintenance of remission in Crohn’s disease
20 Jul, 2023 | 10:51h | UTCVedolizumab for induction and maintenance of remission in Crohn’s disease – Cochrane Library
RCT | Mirikizumab outperforms placebo in inducing and maintaining remission in ulcerative colitis
10 Jul, 2023 | 13:25h | UTCMirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Mirikizumab Bests Placebo in Treating Patients With Ulcerative Colitis – HCP Live
Commentary on Twitter
In two placebo-controlled, phase 3 trials, mirikizumab, a p19-directed anti–interleukin-23 antibody, was superior with regard to clinical remission of ulcerative colitis at 12 weeks (induction) and 40 weeks (maintenance). https://t.co/H4reu33hF1
— NEJM (@NEJM) June 28, 2023
Consensus Paper | Gut microbiota and fecal microbiota transplantation in inflammatory bowel disease
26 Jun, 2023 | 00:26h | UTC
RCT | JAK inhibitor Upadacitinib shows superiority over placebo for moderate-to-severe Crohn’s disease
1 Jun, 2023 | 12:08h | UTCUpadacitinib Induction and Maintenance Therapy for Crohn’s Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Review | Identifying, understanding and managing fecal urgency in inflammatory bowel diseases
4 May, 2023 | 13:38h | UTC
SR | Fecal transplantation for treatment of inflammatory bowel disease
2 May, 2023 | 13:39h | UTCFecal transplantation for treatment of inflammatory bowel disease – Cochrane Library
RCT | Anti-TNF in combination with low dose methotrexate vs anti-TNF monotherapy in pediatric Crohn’s disease
26 Apr, 2023 | 13:55h | UTCComparative Effectiveness of Anti-TNF in Combination with Low Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn’s Disease: a Pragmatic Randomized Trial – Gastroenterology (link to abstract – $ for full-text)
Brief Review | Chronic cough and inflammatory bowel disease: an under-recognized association?
18 Apr, 2023 | 13:07h | UTCChronic cough and inflammatory bowel disease: an under-recognised association? – Breathe
Commentary on Twitter
Breathe: Respiratory complications of inflammatory bowel disease (IBD) are common and may be under-recognised. Chronic cough may present many years after a colectomy for IBD, is typically productive and can be very responsive to inhaled corticosteroids. https://t.co/9hw3bvMeGp pic.twitter.com/ZJURzidpMU
— ERS publications (@ERSpublications) April 15, 2023
RCT | Etrasimod outperforms placebo in ulcerative colitis induction & maintenance
6 Apr, 2023 | 12:56h | UTC
Commentary on Twitter
Just published @TheLancet – Sandborn et al – Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies https://t.co/BVDWtESWLP#gitwitter #ibd #ulcerativecolitis #ECCO23 #ECCO2023 pic.twitter.com/hjyJ0tdtWd
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) March 3, 2023
Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019
5 Apr, 2023 | 13:27h | UTC
RCT | Vedolizumab for the treatment of chronic pouchitis
3 Apr, 2023 | 13:49h | UTCVedolizumab for the Treatment of Chronic Pouchitis – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: New hope for patients after vedolizumab found effective to treat Chronic Pouchitis – University of Oxford
Commentary on Twitter
In a phase 4, double-blind, randomized trial, vedolizumab therapy was more effective than placebo in inducing remission in patients with chronic pouchitis after ileal pouch–anal anastomosis for ulcerative colitis. Full results of EARNEST trial: https://t.co/5OnC72j2Ik pic.twitter.com/RcH1uAB1AI
— NEJM (@NEJM) March 29, 2023
M-A | Has the therapeutical ceiling been reached in Crohn’s disease randomized controlled trials?
17 Mar, 2023 | 12:55h | UTC
RCT | Induction therapy with olamkicept vs. placebo in patients with active ulcerative colitis
13 Mar, 2023 | 14:48h | UTCEffect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis: A Randomized Clinical Trial – JAMA (free for a limited period)
Commentary on Twitter
Among patients with active ulcerative colitis, biweekly infusion of olamkicept 600 mg, but not 300 mg, resulted in a greater likelihood of clinical response at 12 weeks compared with placebo. https://t.co/I9h3jTZxlL pic.twitter.com/hgMvFhdzDa
— JAMA (@JAMA_current) March 8, 2023
Cohort Study | Endoscopic biopsy with normal mucosa associated with elevated risk of inflammatory bowel disease for at least 30 years
8 Mar, 2023 | 14:10h | UTCSummary:
This study explored the long-term risk of inflammatory bowel disease (IBD) after an endoscopic biopsy with normal mucosa. The researchers identified individuals in Sweden with a lower or upper gastrointestinal (GI) biopsy of normal mucosa, their matched population references, and unexposed full siblings.
They found that individuals with a previous lower or upper GI biopsy showing normal mucosa were at persistently higher risk of overall IBD, ulcerative colitis, and Crohn’s disease compared to their matched population references and unexposed full siblings, and the increased risk persisted at least 30 years after the biopsy with normal findings.
The findings suggest a substantial symptomatic period before IBD diagnosis, and clinicians should be aware of the long-term increased risk of IBD in those with symptoms requiring GI investigation but with a finding of histologically normal mucosa.
Commentary: Risk for IBD Remains High After Endoscopic Biopsy With Normal Mucosa – HealthDay
AGA Guideline | Role of biomarkers for the management of ulcerative colitis
22 Feb, 2023 | 12:38h | UTC
Review | Perioperative optimization of Crohn’s disease
17 Feb, 2023 | 12:39h | UTCPerioperative optimization of Crohn’s disease – Annals of Gastroenterological Surgery
Cohort Study | Antibiotics, hormonal therapies, oral contraceptives, and NSAIDS linked to increased risk of inflammatory bowel disease
16 Feb, 2023 | 14:59h | UTCAssociations of Antibiotics, Hormonal Therapies, Oral Contraceptives, and Long-Term NSAIDS With Inflammatory Bowel Disease: Results From the Prospective Urban Rural Epidemiology (PURE) Study – Clinical Gastroenterology and Hepatology (link to abstract – $ for full-text)
Brief Review | Surgical management of ulcerative colitis
13 Feb, 2023 | 12:30h | UTCSurgical management of ulcerative colitis – British Journal of Surgery
ESPEN guideline on clinical nutrition in inflammatory bowel disease
7 Feb, 2023 | 14:02h | UTCESPEN guideline on Clinical Nutrition in inflammatory bowel disease – Clinical Nutrition
RCT | Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy
17 Jan, 2023 | 13:10h | UTCInvited commentary: Treatment withdrawal in Crohn’s disease: slowly becoming clearer – The Lancet Gastroenterology & Hepatology (free registration required)
Commentary on Twitter
New research – Louis et al – Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trialhttps://t.co/T40BmgHtem#IBD #GITwitter #medtwitter pic.twitter.com/iOIbi0WowU
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) January 12, 2023
Cohort Study | Antibiotic exposure linked to increased risk of inflammatory bowel disease
13 Jan, 2023 | 13:25h | UTCNews Release: Frequent use of antibiotics may heighten inflammatory bowel disease risk in over 40s – BMJ Newsroom
Commentaries:
Antibiotics may increase risk of inflammatory bowel disease, study finds – CIDRAP
Antibiotic Exposure Positively Linked to IBD Development – HealthDay
Commentary on Twitter
#GUTPressRelease on the paper by @AdamFayeMD, @KristineAllin, @manasiagrawalmd, @PREDICTIBD et al
"Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study" viahttps://t.co/zc9bG3CpSm#GUTInTheNews pic.twitter.com/xra8wfEgnr
— Gut Journal (@Gut_BMJ) January 9, 2023